LL-37 vs Thymalin.

LL-37 is the only human cathelicidin-derived antimicrobial peptide, a 37-residue cationic, amphipathic alpha-helical peptide (named for its two leading leucine residues) cleaved from the C-terminus of the precursor protein hCAP18 (gene CAMP). It is an endogenous component of innate immunity, produced by neutrophils, epithelial cells, keratinocytes, and other tissues, where it acts as both a broad-spectrum antimicrobial and a host-defense signaling molecule.

Thymalin is a peptide preparation originally isolated as a polypeptide fraction from calf thymus gland, developed by Vladimir Khavinson's group in the Soviet Union and Russia. It belongs to the family of so-called peptide bioregulators and is associated with short peptide sequences (notably Lys-Glu and Glu-Trp) proposed as its active elements. It is positioned as a thymic immunomodulator intended to counter age-related decline of the thymus and T-cell immunity. In Russia it is a registered pharmaceutical; elsewhere it is treated as a research compound.

As a cationic amphipathic peptide, LL-37 binds anionic microbial membranes and disrupts them (a detergent-like/toroidal-pore mechanism), giving broad activity against Gram-positive and Gram-negative bacteria, some fungi, and enveloped viruses, plus the ability to neutralize LPS and disrupt biofilms. Beyond direct killing, it is strongly immunomodulatory: it is chemotactic for neutrophils, monocytes, and T cells (acting partly via the FPR2/FPRL1 receptor), promotes angiogenesis and keratinocyte migration and proliferation (relevant to wound re-epithelialization), and modulates Toll-like-receptor and inflammatory signaling. A double-edged feature is that LL-37 can bind self-DNA/RNA and convert it into a potent activator of plasmacytoid dendritic cells via TLR9/TLR7, a pathway implicated in psoriasis and other autoimmunity.

Thymalin is proposed to act as an immune bioregulator that supports differentiation and function of T-lymphocytes and helps normalize the T-helper/T-suppressor balance. The Khavinson group hypothesizes that its constituent short peptides can enter cells and interact with DNA and chromatin to modulate tissue-specific gene expression, nudging an aged or dysregulated immune system toward a more youthful pattern. Some experimental work reports effects on the differentiation of hematopoietic stem cells. These proposed mechanisms are largely derived from the originating laboratory's own animal and cell studies rather than from independent mechanistic confirmation.

Direct human interventional evidence is limited and centers on chronic wounds. A multicentric, prospective, randomized, placebo-controlled trial evaluated topical LL-37 in hard-to-heal venous leg ulcers (Gronberg et al., Wound Repair Regen, 2021, PMID 34687253), building on an earlier safety/efficacy study reporting improved healing of venous leg ulcers (PMID 25041740); these are small, wound-specific studies rather than large confirmatory trials. The great majority of the LL-37 literature is mechanistic, in vitro, or animal-based: for example, cathelicidin's protective role against urinary-tract infection was shown in mice and human cells (Chromek et al., Nat Med, 2006, PMID 16751768). Much of the peptide's purported breadth (antiviral, anticancer, antibiofilm, metabolic effects) remains preclinical, and endogenous LL-37 biology should not be conflated with proven benefit from administering exogenous LL-37 in humans. Honest summary: human efficacy data exist mainly for topical chronic-wound healing and remain early-stage; systemic therapeutic use is not established.

The published evidence for thymalin comes overwhelmingly from Vladimir Khavinson and collaborators, appearing mainly in Russian-language journals and outlets such as Bulletin of Experimental Biology and Medicine and Neuro Endocrinology Letters. The most cited human data is a multi-year, non-blinded geroprotection program in elderly subjects reporting improved immune parameters and lower mortality versus controls, but it was not a modern blinded, independently replicated randomized controlled trial. That program was reported retrospectively across several summary papers rather than as a single prespecified protocol, and the published accounts do not describe randomization procedure, allocation concealment, blinded outcome assessment, prespecified primary endpoints, or independent data monitoring. Companion reviews such as the 2002 Neuro Endocrinology Letters paper on peptides and ageing present thymalin alongside epithalamin as part of a single geroprotective program, so the human results for the two preparations are frequently reported together rather than separately. More recent papers describe effects on hematopoietic stem cell differentiation and gene expression, again largely from the same group and largely in cell culture, including work on peptide regulation of immune and inflammatory pathways in spleen tissue and in monocyte and macrophage cell lines. Independent Western replication in rigorous RCTs is essentially absent, so the evidence base should be read as preliminary and heavily single-source. Readers should weigh the near-total reliance on one research group when interpreting any claims. The contrast with Cerebrolysin is a useful calibration: Cerebrolysin, another animal-tissue peptide preparation, has accumulated enough independent randomized trials to support two Cochrane systematic reviews, and those reviews still reached cautious and largely non-endorsing conclusions. Thymalin has not reached even that level of external scrutiny, and it shares this position with the other bioregulators in the same tradition, notably vilon, cortexin and epitalon. What is not known is substantial: there is no published modern toxicology package, no pharmacokinetic characterization of the fraction in humans, no batch-to-batch potency standard visible in the international literature, and no registration-quality trial outside Russia.

LL-37 has a genuinely double-edged profile: the same self-nucleic-acid-binding and dendritic-cell-activating activity that aids host defense is mechanistically implicated in autoimmune and inflammatory disease, and LL-37 is recognized as an autoantigen targeted by T cells in psoriasis. Elevated or dysregulated cathelicidin has also been linked to rosacea, lupus, atherosclerosis, and a context-dependent (pro- or anti-) role in cancer, so effects are highly tissue- and concentration-dependent. At higher concentrations the peptide can be cytotoxic and hemolytic to host cells, and it can be degraded or inactivated by serum and proteases, complicating systemic delivery. Human safety data are essentially confined to localized topical wound use; the safety of exogenous systemic administration in humans is not established.

Reported human and animal experience describes thymalin as generally well tolerated in the contexts studied, with few documented serious adverse effects in the originating literature. However, because independent long-term safety data and modern regulatory review outside Russia are lacking, its safety profile in broad populations is not well established, and the absence of reported harms in single-group publications is weak evidence of safety rather than positive evidence of it. As a parenteral preparation derived from calf tissue, it carries the generic concerns that apply to all animal-sourced injectable biologicals: hypersensitivity and anaphylactoid reactions to foreign protein, immunogenicity on repeated exposure, injection-site reactions, and dependence on the source herd and the purification process for freedom from adventitious agents. An agent proposed to modulate T-cell function also raises a theoretical question in autoimmune disease and in people taking immunosuppressive therapy, and that question has not been studied. Product purity and identity are also uncertain for material obtained outside regulated pharmaceutical channels, where lyophilized vials sold as research chemicals carry no verified sterility, endotoxin or content assay. A genuine safety evaluation would require what the existing literature does not provide: prospective adverse-event capture, immunological and hepatic and renal laboratory monitoring, anti-drug antibody testing, and follow-up long enough to detect delayed effects. This is educational information only and not medical or dosing advice.

LL-37 is not an FDA-approved drug; it is an endogenous human peptide studied as an investigational and research-use agent. Clinical work has been early-phase and indication-specific (notably topical chronic-wound trials), and no LL-37 product holds general marketing approval.

Thymalin is registered and used as an approved medicine in Russia, where it has a long clinical history. It is not approved by the US FDA or the European Medicines Agency and has no approved indication in the US, where it would be considered an unapproved research substance. It is not a dietary supplement.